The correlation of apolipoprotein B and apolipoprotein A1 with metabolic dysfunction-associated steatotic liver disease in children and adolescents with obesity
Xiao-Yan Shi
Children's Health Management Center, Children's Hospital of Soochow University, Suzhou, China
Search for more papers by this authorYa-Kun Liu
General Surgery Department, Children's Hospital of Soochow University, Suzhou, China
Search for more papers by this authorYan Chen
Department of Children Health Care, Children's Hospital of Soochow University, Suzhou, China
Search for more papers by this authorZhi-Ying Jiang
Department of Children Health Care, Children's Hospital of Soochow University, Suzhou, China
Search for more papers by this authorMeng-Xuan Ye
Department of Children Health Care, Children's Hospital of Soochow University, Suzhou, China
Search for more papers by this authorCorresponding Author
Jian Wang
Pediatric Research Institute of Soochow University, Children's Hospital of Soochow University, Suzhou, China
Correspondence
Jian Wang, Pediatric Research Institute of Soochow University, Children's Hospital of Soochow University, No. 92 Zhongnan Street, Suzhou, Jiangsu, 215123, China.
Email: [email protected]
Search for more papers by this authorXiao-Yan Shi
Children's Health Management Center, Children's Hospital of Soochow University, Suzhou, China
Search for more papers by this authorYa-Kun Liu
General Surgery Department, Children's Hospital of Soochow University, Suzhou, China
Search for more papers by this authorYan Chen
Department of Children Health Care, Children's Hospital of Soochow University, Suzhou, China
Search for more papers by this authorZhi-Ying Jiang
Department of Children Health Care, Children's Hospital of Soochow University, Suzhou, China
Search for more papers by this authorMeng-Xuan Ye
Department of Children Health Care, Children's Hospital of Soochow University, Suzhou, China
Search for more papers by this authorCorresponding Author
Jian Wang
Pediatric Research Institute of Soochow University, Children's Hospital of Soochow University, Suzhou, China
Correspondence
Jian Wang, Pediatric Research Institute of Soochow University, Children's Hospital of Soochow University, No. 92 Zhongnan Street, Suzhou, Jiangsu, 215123, China.
Email: [email protected]
Search for more papers by this authorSummary
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) has become a prevalent liver condition in children and teenagers with obesity. Unfortunately, there is no standardized treatment.
Objective
To examine the connection between apolipoprotein B (apoB), apolipoprotein A1 (apoA1), and the apoB/apoA1 ratio with the occurrence of MASLD in this population.
Methods
A retrospective study was made on children and adolescents with obesity in a children's hospital between the period 2020 and 2022. Anthropometric data, ultrasound results, and blood biochemistry were analysed to assess the connection between apoB, apoA1, and the presence of MASLD.
Results
Of the 916 participants included, 313 were diagnosed with MASLD. The level of serum apoB reflected a substantial dose–response correlation with the odds of having MASLD. When apoB levels exceeded the 50th percentile, the risk increased significantly, and at the 95th percentile, the odds were 4.83 times higher than at the 50th percentile (95% CI: 2.02–11.56). The ratio of apoB/apoA1 at the 95th percentile was connected to a 2.41-fold higher prevalence compared to the 50th percentile (95% CI: 1.33–4.37). No significant correlation was found between the levels of apoA1 and MASLD prevalence.
Conclusion
Elevated levels of apoB and the apoB/apoA1 ratio have been strongly connected to increased MASLD prevalence in children and adolescents with obesity; hence, signifying their potential usefulness as biomarkers for early detection and intervention.
CONFLICT OF INTEREST STATEMENT
The authors have no competing interests to report.
Open Research
DATA AVAILABILITY STATEMENT
The datasets used or analyzed during the current study are available from the corresponding author on reasonable request.
Supporting Information
| Filename | Description |
|---|---|
| ijpo70017-sup-0001-Supinfo.pdfPDF document, 110.6 KB | DATA S1. Supporting Information. |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2014; 384(9945): 766-781.
- 2 European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024; 81(3): 492-542.
- 3Sahota AK, Shapiro WL, Newton KP, Kim ST, Chung J, Schwimmer JB. Incidence of nonalcoholic fatty liver disease in children: 2009-2018. Pediatrics. 2020; 146(6):e20200771. doi:10.1542/peds.2020-0771
- 4Liu J, Mu C, Li K, Luo H, Liu Y, Li Z. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese children and adolescents: systematic review and meta-analysis. Int J Public Health. 2021; 66:1604371.
- 5Anderson EL, Howe LD, Jones HE, Higgins JPT, Lawlor DA, Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis. PLoS One. 2015; 10(10):e0140908.
- 6Zhang W, Wei L. Prevalence of non-alcoholic fatty liver disease in Asia. Chin J Hepatol. 2013; 21(11): 801-804.
- 7Lee EJ, Choi M, Ahn SB, et al. Prevalence of nonalcoholic fatty liver disease in pediatrics and adolescents: a systematic review and meta-analysis. World J Pediatr. 2024; 20(6): 569-580.
- 8Nobili V, Alisi A, Newton KP, Schwimmer JB. Comparison of the phenotype and approach to pediatric vs adult patients with nonalcoholic fatty liver disease. Gastroenterology. 2016; 150(8): 1798-1810.
- 9Lonardo A, Byrne CD, Caldwell SH, Cortez-Pinto H, Targher G. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64(4): 1388-1389.
- 10Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016; 31(5): 936-944.
- 11Shapiro WL, Noon SL, Schwimmer JB. Recent advances in the epidemiology of nonalcoholic fatty liver disease in children. Pediatr Obes. 2021; 16(11):e12849.
- 12Richardson TG, Sanderson E, Palmer TM, et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: a multivariable Mendelian randomisation analysis. PLoS Med. 2020; 17(3):e1003062.
- 13Wang J, Zhu W, Huang S, et al. Serum apoB levels independently predict the development of non-alcoholic fatty liver disease: a 7-year prospective study. Liver Int. 2017; 37(8): 1202-1208.
- 14Huang H, Wang J, Xu L, Miao M, Xu C. Association between high-density lipoprotein cholesterol to Apolipoprotein A-I ratio and nonalcoholic fatty liver disease: a cross-sectional study. Int J Endocrinol. 2021; 2021:6676526.
- 15Guo Q, Zhang C, Wang Y. Overexpression of apolipoprotein A-I alleviates endoplasmic reticulum stress in hepatocytes. Lipids Health Dis. 2017; 16(1): 105.
- 16Yang MH, Sung J, Gwak GY. The associations between apolipoprotein B, A1, and the B/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population. J Clin Lipidol. 2016; 10(2): 289-298.
- 17Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023; 151(2):e2022060640.
- 18Vos MB, Abrams SH, Barlow SE, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the north American Society of Pediatric Gastroenterology, Hepatology and nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017; 64(2): 319-334.
- 19Farrell GC, Chitturi S, Lau GK, Sollano JD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J Gastroenterol Hepatol. 2007; 22(6): 775-777. doi:10.1111/j.1440-1746.2007.05002.x
- 20 NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024; 403(10431): 1027-1050. doi:10.1016/S0140-6736(23)02750-2
- 21Tim Lobstein HB. Atlas of childhood obesity. World Obesity Federation; 2019.
- 22Clemente MG, Mandato C, Poeta M, Vajro P. Pediatric non-alcoholic fatty liver disease: recent solutions, unresolved issues, and future research directions. World J Gastroenterol. 2016; 22(36): 8078-8093.
- 23Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67(1): 328-357.
- 24Navarro-Jarabo JM, Ubiña-Aznar E, Tapia-Ceballos L, et al. Hepatic steatosis and severity-related factors in obese children. J Gastroenterol Hepatol. 2013; 28(9): 1532-1538.
- 25Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012; 55(4): 885-904.
- 26Podnar H, Juric P, Karuc J, et al. Comparative effectiveness of school-based interventions targeting physical activity, physical fitness or sedentary behaviour on obesity prevention in 6- to 12-year-old children: a systematic review and meta-analysis. Obes Rev. 2021; 22(2):e13160.
- 27Torbahn G, Jones A, Griffiths A, et al. Pharmacological interventions for the management of children and adolescents living with obesity-an update of a Cochrane systematic review with meta-analyses. Pediatr Obes. 2024; 19(5):e13113.
- 28Zhou H, Luo P, Li P, et al. Bariatric surgery improves nonalcoholic fatty liver disease: systematic review and meta-analysis. Obes Surg. 2022; 32(6): 1872-1883.
- 29 Obesity and Diabetes Surgeons Committee, Surgeons Branch of the Chinese Medical Doctor Association. Guidelines for the surgical treatment of obesity in children and adolescents in China (2019 edition). Chin J Obes Metab Dis. 2019; 5(1): 3-9.
- 30Remaley AT, Cole J, Sniderman AD. ApoB is ready for prime time. J Am Coll Cardiol. 2024; 83(23): 2274-2275.
- 31Sasongko MB, Wong TY, Nguyen TT, et al. Serum apolipoprotein AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids. Diabetes Care. 2011; 34(2): 474-479.
- 32Zhao Y. Association between apolipoprotein B/A1 and the risk of metabolic dysfunction associated fatty liver disease according to different lipid profiles in a Chinese population: a cross-sectional study. Clin Chim Acta. 2022; 534: 138-145.
- 33AK M, Mantan M, Mahajan B. Serum apolipoproteins (apoA-1, apoB, and apoB/apoA-1 ratio) for early identification of dyslipidemia in children with CKD. Pediatr Nephrol. 2024; 39(3): 849-856.
- 34Rodríguez-Moran M, Aradillas-García C, Guerrero-Romero F. The ApoB/A-I ratio and metabolic syndrome in prepubertal children. Metab Syndr Relat Disord. 2013; 11(2): 115-120.
- 35Lee Y, Doumouras AG, Yu J, et al. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019; 17(6): 1040-1060.e11.
- 36Mantovani A, Byrne CD, Scorletti E, Mantzoros CS, Targher G. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: an updated systematic review of randomized controlled trials. Diabetes Metab. 2020; 46(6): 427-441.
- 37Haas ME, Attie AD, Biddinger SB. The regulation of ApoB metabolism by insulin. Trends Endocrinol Metab. 2013; 24(8): 391-397.
- 38Burnett JR, Hooper AJ, Hegele RA. APOB-related familial hypobetalipoproteinemia. In: MP Adam, J Feldman, GM Mirzaa, et al., eds. GeneReviews®. University of Washington, Seattle; 2021.
- 39Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010; 51(2): 679-689.
- 40Semenova E, Guo A, Liang H, Hernandez CJ, John EB, Thaker VV. The expanding landscape of genetic causes of obesity. Pediatr Res. 2024. doi:10.1038/s41390-024-03780-6
- 41Zhao Y, Chukanova M, Kentistou KA, et al. Protein-truncating variants in BSN are associated with severe adult-onset obesity, type 2 diabetes and fatty liver disease. Nat Genet. 2024; 56(4): 579-584.
- 42Walldius G, Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy: a review of the evidence. J Intern Med. 2006; 259(5): 493-519.
- 43Fisher EA, Feig JE, Hewing B, Hazen SL, Smith JD. High-density lipoprotein function, dysfunction, and reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 2012; 32(12): 2813-2820.
- 44Jackson AO, Rahman GA, Long S. Apolipoprotein-AI and AIBP synergetic anti-inflammation as vascular diseases therapy: the new perspective. Mol Cell Biochem. 2021; 476(8): 3065-3078.
- 45Wang Y, Li X, Gao Y, Zhang X, Liu Y, Wu Q. Risk factors for non-alcoholic fatty liver disease in patients with bipolar disorder: a cross-sectional retrospective study. Diabetes Metab Syndr Obes. 2024; 17: 3053-3061.
- 46Rubin DA, McMurray RG, Harrell JS, Hackney AC, Thorpe DE, Haqq AM. The association between insulin resistance and cytokines in adolescents: the role of weight status and exercise. Metabolism. 2008; 57(5): 683-690. doi:10.1016/j.metabol.2008.01.005
- 47Hagman E, Besor O, Hershkop K, et al. Relation of the degree of obesity in childhood to adipose tissue insulin resistance. Acta Diabetol. 2019; 56(2): 219-226.
- 48Rajewski P, Cieściński J, Rajewski P, Suwała S, Rajewska A, Potasz M. Dietary interventions and physical activity as crucial factors in the prevention and treatment of metabolic dysfunction-associated Steatotic liver disease. Biomedicine. 2025; 13(1): 217.
- 49Pei Y, Goh GB. Genetic risk factors for metabolic dysfunction-associated steatotic liver disease. Gut Liver. 2025; 19(1): 8-18.
- 50Lipp D. A study comparing three techniques for the detection of HAA. Am J Med Technol. 1972; 38(11): 446-453.
- 51Weng W. Association of serum apolipoprotein B and A1 and their ratio with coronary artery disease in patients with coronary heart disease and metabolic syndrome. Chin J Clin Ration Drug Use. 2019; 12(4): 9-10.
- 52Wu J, Wang Y, Li H, Tan W, Chen X, Ye S. Serum apolipoprotein B-to-apolipoprotein A1 ratio is independently associated with disease severity in patients with acute pancreatitis. Sci Rep. 2019; 9(1): 7764.
- 53Bohte AE, van Werven JR, Bipat S, Stoker J. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol. 2011; 21(1): 87-97.
- 54Liu J, Ayada I, Zhang X, et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol. 2022; 20(3): e573-e582.
